Stephens & Co. Maintains Overweight on Pacific Biosciences, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico maintains an Overweight rating on Pacific Biosciences (NASDAQ:PACB) but lowers the price target from $3.5 to $2.5.
August 13, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stephens & Co. analyst Mason Carrico maintains an Overweight rating on Pacific Biosciences but lowers the price target from $3.5 to $2.5.
The lowered price target from $3.5 to $2.5 suggests a less optimistic outlook for Pacific Biosciences, which could negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100